EZ DERM LLC

EZDERM dermatology EHR (Ezehr plus Ezpm suite)

Ezderm · Review dated 2026-10-13

No published numeric EZDERM rate found. Official FAQ says pricing varies by practice size and needs and directs buyers to sales for an accurate quote; it also states pricing is transparent with no hidden fees. Official Ezpay page says flat-rate processing with no setup, monthly, or hidden costs and lower card-present rates, but gives no dollar or percentage amounts. Ezportal is explicitly included with the core software at no extra fee. Official FAQ search result states system access begins on signing and billing typically begins at go-live; no free trial, minimum term, cancellation term, or promotional numeric rate was disclosed.

Billing model

Quote-based / not publicly disclosed. Vendor describes pricing as scalable and practice-size/needs dependent; no numeric subscription, per-provider, per-encounter, monthly, annual, minimum, or contract amount was published on the official pages checked.

Fees and add-ons

Implementation/migration: Ezswitch is a guided transition program covering patient demographics, documents, appointments/schedules, balances, credits, CCDA files and records; tailored milestones, workflow build, go-live coordination, a dedicated Implementation Specialist, 20 complimentary hours of 1:1 virtual onboarding, 5 complimentary virtual-training hours annually, 3 hours for each new provider, and Ezschool self-paced training. Timeline: official FAQ search result says plan for 6–8 weeks; billing typically starts at go-live. RCM: integrated charge capture/superbills, CPT/ICD flow, claim scrubbing, Availity electronic submission, primary/secondary claims, denial follow-up, ERA/EOB posting, patient statements and collections; no RCM fee or percentage published. Payments: Ezpay powered by Square supports terminal/reader, card-on-file, SMS/email links, website payments, next-business-day deposits, flat-rate pricing; amount not published. Interfaces/integrations: Surescripts pharmacy history/eligibility/formulary, Healthmonix MIPS integration, Availity clearinghouse, lab/pathology integration, and Medsender API integration for document/referral routing; Medsender was stated to be available to beta customers. Eve AI is a current product page labeled “Coming Soon”; Eve RCM Complete says software is included at no additional cost with that service, but service pricing is not published. No official telehealth pricing or dedicated telehealth product/feature was found on checked pages; do not infer that portal/mobile access is telehealth.

Availability and public pricing

Current official vendor materials position Ezderm as a full dermatology clinical EHR, not merely practice management: Ezehr includes 3D body mapping, Mohs, isotretinoin/iPLEDGE, pathology/biopsy, malignancy tracking, clinical reports, MIPS, e-prescribing, Surescripts, and Apple-device access; Ezpm is tightly integrated with it in one unified platform. ONC 2015 Edition/Meaningful Use certification is claimed, with 2022–2024 real-world testing links. The March 24, 2026 official announcement says the previously closed API is opening first to preferred partners, with Medsender the first integration and broader API expansion planned. Product pages list ezehr, ezpm, ezrcm, ezpay, ezengage, ezportal, ezswitch, and Eve AI. Prices are quote-based; no legacy, promotional, or customer-specific numeric price was located in official sources.

Qualifications

Evidence was limited to official Ezderm-owned pages and vendor-hosted PDFs; no third-party aggregators or snippets were used as pricing evidence. Some FAQ answers are accordion/dynamically rendered and were not present in the extracted page body; the 6–8-week implementation and go-live billing statements were visible in official FAQ search indexing for the opened FAQ URL. No numeric rate, trial, minimum, term, telehealth offering, or separate e-prescribing fee was publicly disclosed. Ezpay’s “flat-rate” wording does not establish a numeric rate. Eve AI is explicitly future/coming-soon, and Medsender availability was explicitly beta-customer limited at announcement.